EGFR and colorectal cancer: The introduction of a novel class of targeted antineoplastic agents, such as those directed against the EGFR, have notably expanded the available therapeutic options for patients with advanced colorectal cancer (Cunningham et al, 2004; Ellis and Hoff, 2004).